Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Eculizumab, sold under the trade name Soliris, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PHN) and atypical hemolytic uremic syndrome (aHUS). It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted on the basis of small clinical trials.
In recent years, Solilis Asia Pacific market has developed rapidly. However, with the development of the economic situation in the Asia-Pacific region, other companies have entered the industry one after another; prices will decline in the next five years.Soliris is widely used in patients such as PNH and aHUS. PNH patients have the highest proportion of Soliris.Japan is the world's largest consumer market, and China is the second largest consumer market after Japan.Market competition is not intense. Soliris (eculizumab) is the first and only drug approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome (aHUS). PNH and aHUS It is caused by long-term uncontrolled activation of the complement component of the immune system.
The report details the trend, potential and market size of Soliris (Eculizumab) market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Soliris (Eculizumab)market, defines the market attractiveness level of Soliris (Eculizumab) market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Soliris (Eculizumab) industry, describes the types of Soliris (Eculizumab) market, the applications of major players and the market size, and deeply analyzes the current situation of the global Soliris (Eculizumab) market and the development prospects and opportunities of Soliris (Eculizumab) industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Soliris (Eculizumab) market in Chapter 13.
By Player:
Alexion
By Type:
Plasma Exchange
Plasma Infusion
By End-User:
PNH
AHUS
Others
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Soliris (Eculizumab) Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Soliris (Eculizumab) Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Soliris (Eculizumab) Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Soliris (Eculizumab) Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Soliris (Eculizumab) Market Analysis and Outlook to 2022
-
7.1 Global Soliris (Eculizumab) Consumption (2017-2022)
-
7.2 United States Soliris (Eculizumab) Consumption (2017-2022)
-
7.3 Europe Soliris (Eculizumab) Consumption (2017-2022)
-
7.4 China Soliris (Eculizumab) Consumption (2017-2022)
-
7.5 Japan Soliris (Eculizumab) Consumption (2017-2022)
-
7.6 India Soliris (Eculizumab) Consumption (2017-2022)
-
7.7 South Korea Soliris (Eculizumab) Consumption (2017-2022)
8 Region and Country-wise Soliris (Eculizumab) Market Analysis and Outlook to 2028
-
8.1 Global Soliris (Eculizumab) Consumption Forecast (2022-2028)
-
8.2 United States Soliris (Eculizumab) Consumption Forecast (2022-2028)
-
8.3 Europe Soliris (Eculizumab) Consumption Forecast (2022-2028)
-
8.4 China Soliris (Eculizumab) Consumption Forecast (2022-2028)
-
8.5 Japan Soliris (Eculizumab) Consumption Forecast (2022-2028)
-
8.6 India Soliris (Eculizumab) Consumption Forecast (2022-2028)
-
8.7 South Korea Soliris (Eculizumab) Consumption Forecast (2022-2028)
9 Global Soliris (Eculizumab) Market Outlook by Types and Applications to 2022
-
9.1 Global Soliris (Eculizumab) Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Plasma Exchange Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Plasma Infusion Consumption and Growth Rate (2017-2022)
-
9.2 Global Soliris (Eculizumab) Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global PNH Consumption and Growth Rate (2017-2022)
-
9.2.2 Global AHUS Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Others Consumption and Growth Rate (2017-2022)
10 Global Soliris (Eculizumab) Market Outlook by Types and Applications to 2028
-
10.1 Global Soliris (Eculizumab) Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Plasma Exchange Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Plasma Infusion Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Soliris (Eculizumab) Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global PNH Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global AHUS Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)
11 Global Soliris (Eculizumab) Import and Export Analysis (Top 5 Countries)
-
11.1 Global Soliris (Eculizumab) Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Soliris (Eculizumab) Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Soliris (Eculizumab) Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Soliris (Eculizumab) Market Competitive Analysis
-
14.1 Alexion
-
14.1.1 Alexion Company Details
-
14.1.2 Alexion Soliris (Eculizumab) Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Alexion Soliris (Eculizumab) Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Soliris (Eculizumab)
-
Figure Soliris (Eculizumab) Picture
-
Table Global Soliris (Eculizumab) Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Soliris (Eculizumab) Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Soliris (Eculizumab) Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Soliris (Eculizumab) Consumption by Country (2017-2022)
-
Figure United States Soliris (Eculizumab) Consumption and Growth Rate (2017-2022)
-
Table Europe Soliris (Eculizumab) Consumption and Growth Rate (2017-2022)
-
Figure China Soliris (Eculizumab) Consumption and Growth Rate (2017-2022)
-
Figure Japan Soliris (Eculizumab) Consumption and Growth Rate (2017-2022)
-
Figure India Soliris (Eculizumab) Consumption and Growth Rate (2017-2022)
-
Figure South Korea Soliris (Eculizumab) Consumption and Growth Rate (2017-2022)
-
Figure Global Soliris (Eculizumab) Consumption Forecast by Country (2022-2028)
-
Figure United States Soliris (Eculizumab) Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Soliris (Eculizumab) Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Soliris (Eculizumab) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Soliris (Eculizumab) Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Soliris (Eculizumab) Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Soliris (Eculizumab) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Plasma Exchange Consumption and Growth Rate (2017-2022)
-
Figure Global Plasma Infusion Consumption and Growth Rate (2017-2022)
-
Figure Global PNH Consumption and Growth Rate (2017-2022)
-
Figure Global AHUS Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Plasma Exchange Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Plasma Infusion Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global PNH Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global AHUS Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Soliris (Eculizumab) Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Soliris (Eculizumab) Export by Region (Top 5 Countries) (2017-2028)
-
Table Alexion (Foundation Year, Company Profile and etc.)
-
Table Alexion Soliris (Eculizumab) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Alexion Soliris (Eculizumab) Product and Service
-
